SynthesisPloS one2013
Association between XRCC1 and XRCC3 polymorphisms with lung cancer risk: a meta-analysis from case-control studies.
Synthesis in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 5 syntheses or guidelines pooled it, 24 citations in OpenAlex.
- Association between XRCC3 rs861539 Polymorphism and the Risk of Ovarian Cancer: Meta-Analysis and Trial Sequential Analysis.BioMed research international · 2022Pooled it
- Association Between X-Ray Cross-complementing Group 3 (XRCC3) Thr241Met Polymorphism and Risk of Thyroid Cancer: A Meta-Analysis.Medical science monitor : international medical journal of experimental and clinical research · 2015Pooled it
- Gene-gene and gene-environment interactions in meta-analysis of genetic association studies.PloS one · 2015Pooled it
- Association between TNF-α gene 308G>A polymorphism and lung cancer risk: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- XRCC1 Arg399Gln polymorphism confers risk of breast cancer in American population: a meta-analysis of 10846 cases and 11723 controls.PloS one · 2014Pooled it
- Article
- Impact of Interaction between Single Nucleotide Polymorphism of XRCC1, XRCC2, XRCC3 with Tumor Suppressor Tp53 Gene Increases Risk of Breast Cancer: A Hospital Based Case-Control Study.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- Associations between polymorphisms in genes of base excision repair pathway and lung cancer risk.Translational cancer research · 2020Article
- Association of -77T>C and Arg194trp polymorphisms of XRCC1 with risk of coronary artery diseases in Iranian population.Iranian journal of basic medical sciences · 2016Article
- XRCC3 Thr241Met Polymorphism is not Associated with Lung Cancer Risk in a Romanian Population.Clujul medical (1957) · 2016Article
- Homologous Recombination Repair Polymorphisms and the Risk for Osteosarcoma.Journal of medical biochemistry · 2015Article
- The relationship between genetic variants of XRCC1 gene and lung cancer susceptibility in Chinese Han population.Medical oncology (Northwood, London, England) · 2014Article
- The association of c.1471G>A genetic polymorphism in XRCC1 gene with lung cancer susceptibility in Chinese Han population.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many studies have reported the association of X-ray repair cross-complementing group 1 (XRCC1) Arg399Gln, Arg194Trp, Arg280His, -77T>C, and X-ray repair cross-complementing group 3 (XRCC3) T241M polymorphisms with lung cancer risk, but the results remained controversial. Hence, we performed a meta-analysis to investigate the association between lung cancer risk and XRCC1 Arg399Gln (14,156 cases and 16,667 controls from 41 studies), Arg194Trp (7,426 cases and 9,603 controls from 23 studies), Arg280His (6,211 cases and 6,763 controls from 16 studies), -77T>C (2,487 cases and 2,576 controls from 5 studies), and XRCC3 T241M (8,560 cases and 11,557 controls from 19 studies) in different inheritance models. We found that -77T>C polymorphism was associated with increased lung cancer risk (dominant model: odds ration [OR] = 1.45, 95% confidence interval [CI] = 1.27-1.66, recessive model: OR = 1.73, 95% CI = 1.14-2.62, additive model: OR = 1.91, 95% CI = 1.24-1.94) when all the eligible studies were pooled into the meta-analysis. In the stratified and sensitive analyses, significantly decreased lung cancer risk was observed in overall analysis (dominant model: OR = 0.83, 95% CI = 0.78-0.89; recessive model: OR = 0.90, 95% CI = 0.81-1.00; additive model: OR = 0.82, 95% CI = 0.74-0.92), Caucasians (dominant model: OR = 0.82, 95% CI = 0.76-0.87; recessive model: OR = 0.89, 95% CI = 0.80-0.99; additive model: OR = 0.81, 95% CI = 0.73-0.91), and hospital-based controls (dominant model: OR = 0.81, 95% CI = 0.76-0.88; recessive model: OR = 0.89, 95% CI = 0.79-1.00; additive model: OR = 0.80, 95% CI = 0.71-0.90) for XRCC3 T241M. In conclusion, this meta-analysis indicates that XRCC1 -77T>C shows an increased lung cancer risk and XRCC3 T241M polymorphism is associated with decreased lung cancer risk, especially in Caucasians.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.